Ligand Pharmaceuticals Incorporated Stock Price, News & Analysis (NASDAQ:LGND)

$140.31 -1.40 (-0.99 %)
(As of 11/17/2017 04:00 PM ET)
Previous Close$141.71
Today's Range$139.54 - $141.05
52-Week Range$95.08 - $149.31
Volume251,757 shs
Average Volume248,087 shs
Market Capitalization$3.06177 billion
P/E Ratio109.07
Dividend YieldN/A
Beta0.94

About Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

Ligand Pharmaceuticals Incorporated logoLigand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company is involved in the development and licensing of biopharmaceutical assets. The Company employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals. As of December 31, 2016, it had partnerships and license agreements with over 85 pharmaceutical and biotechnology companies, and over 140 various programs under license with it were in various stages of commercialization and development. It has contributed research and technologies for approved medicines that treat cancer, osteoporosis, fungal infections and low blood platelets, among others.


Industry, Sector and Symbol:
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: Biotechnology
  • Sector: Medical
  • Symbol: NASDAQ:LGND
  • CUSIP: 53220K50
  • Web: www.ligand.com
Debt:
  • Debt-to-Equity Ratio: 0.05%
  • Current Ratio: 0.97%
  • Quick Ratio: 0.95%
Price-To-Earnings:
  • Trailing P/E Ratio: 109.07
  • Forward P/E Ratio: 59.71
  • P/E Growth: 2.24
Sales & Book Value:
  • Annual Sales: $108.97 million
  • Price / Sales: 27.17
  • Cash Flow: $0.93 per share
  • Price / Cash: 150.15
  • Book Value: $19.10 per share
  • Price / Book: 7.35
Profitability:
  • Trailing EPS: $0.69
  • Net Income: ($1,630,000.00)
  • Net Margins: 12.76%
  • Return on Equity: 7.83%
  • Return on Assets: 4.64%
Misc:
  • Employees: 22
  • Outstanding Shares: 21,100,000
 

Frequently Asked Questions for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

What is Ligand Pharmaceuticals Incorporated's stock symbol?

Ligand Pharmaceuticals Incorporated trades on the NASDAQ under the ticker symbol "LGND."

How were Ligand Pharmaceuticals Incorporated's earnings last quarter?

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) posted its quarterly earnings data on Thursday, November, 9th. The biotechnology company reported $0.69 EPS for the quarter, beating analysts' consensus estimates of $0.37 by $0.32. The biotechnology company earned $33.38 million during the quarter, compared to analysts' expectations of $31.04 million. Ligand Pharmaceuticals Incorporated had a return on equity of 7.83% and a net margin of 12.76%. Ligand Pharmaceuticals Incorporated's revenue for the quarter was up 54.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.62 earnings per share. View Ligand Pharmaceuticals Incorporated's Earnings History.

When will Ligand Pharmaceuticals Incorporated make its next earnings announcement?

Ligand Pharmaceuticals Incorporated is scheduled to release their next quarterly earnings announcement on Thursday, February, 22nd 2018. View Earnings Estimates for Ligand Pharmaceuticals Incorporated.

What guidance has Ligand Pharmaceuticals Incorporated issued on next quarter's earnings?

Ligand Pharmaceuticals Incorporated updated its FY17 earnings guidance on Tuesday, November, 14th. The company provided earnings per share (EPS) guidance of $2.95-3.00 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.99. The company issued revenue guidance of $134-136 million, compared to the consensus revenue estimate of $136.89 million.

Where is Ligand Pharmaceuticals Incorporated's stock going? Where will Ligand Pharmaceuticals Incorporated's stock price be in 2017?

5 brokers have issued twelve-month price objectives for Ligand Pharmaceuticals Incorporated's shares. Their predictions range from $104.00 to $170.00. On average, they anticipate Ligand Pharmaceuticals Incorporated's share price to reach $145.60 in the next year. View Analyst Ratings for Ligand Pharmaceuticals Incorporated.

What are Wall Street analysts saying about Ligand Pharmaceuticals Incorporated stock?

Here are some recent quotes from research analysts about Ligand Pharmaceuticals Incorporated stock:

  • 1. According to Zacks Investment Research, "Ligand’s Captisol formulation technology has resulted in partnerships with several leading drug companies like Novartis and Amgen that provide it with funds in the form of milestone and royalty payments. Moreover, with regard to Ligand's internal pipeline, there are several candidates in development that could bring in future licensing opportunities. Nonetheless, Ligand’s entry into the Medical Devices Segment with the acquisition of multiple programs owned by CorMatrix is also encouraging. Shares of Ligand have outperformed the broader industry this year so far. However, the company derives a substantial portion of its revenues from royalties associated with the sales of Promacta and Kyprolis. Any setback related to either of these two products could have a substantial impact. Estimates have remained stable ahead of the Q3 earnings. The company has a mixed record of earnings surprises in the recent quarters." (10/12/2017)
  • 2. HC Wainwright analysts commented, "core long term holding" for investors. The firm's Joseph Pantginis initiated coverage of the biopharmaceutical company with a Buy rating and $150 price target, mostly due to the company's business model.Ligand seeks out value-based acquisitions of companies and technologies that have led to both current and anticipated revenue streams, Pantginis commented in his initiation note. This has also resulted in the company's reputation of reporting sustained profitability.Ligand is also an early pioneer of contingent value rights for its acquisitions, the analyst continued. As such, earnings growth is supported by the company's increasing royalty streams that are also a "significant spreading out of risk" (9/5/2017)

Who are some of Ligand Pharmaceuticals Incorporated's key competitors?

Who are Ligand Pharmaceuticals Incorporated's key executives?

Ligand Pharmaceuticals Incorporated's management team includes the folowing people:

  • Matthew W. Foehr, President, Chief Operating Officer (Age 44)
  • John L. Higgins, Chief Executive Officer, Director (Age 47)
  • Matthew E. Korenberg, Chief Financial Officer, Vice President - Finance (Age 42)
  • Charles S. Berkman J.D., Vice President, General Counsel, Secretary (Age 48)
  • John W. Kozarich, Non-Executive Independent Chairman of the Board (Age 67)
  • Nancy Ryan Gray, Director (Age 58)
  • Jason M. Aryeh, Independent Director (Age 48)
  • Todd C. Davis, Independent Director (Age 56)
  • John L. LaMattina Ph.D., Independent Director (Age 67)

Who owns Ligand Pharmaceuticals Incorporated stock?

Ligand Pharmaceuticals Incorporated's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Janus Henderson Group PLC (3.58%), Victory Capital Management Inc. (3.14%), Eagle Asset Management Inc. (2.49%), Macquarie Group Ltd. (2.35%), Stephens Investment Management Group LLC (2.29%) and Oak Ridge Investments LLC (2.22%). Company insiders that own Ligand Pharmaceuticals Incorporated stock include Charles S Berkman, Jason Aryeh, John L Higgins, John W Kozarich, Matthew E Korenberg, Matthew W Foehr and Melanie J Herman. View Institutional Ownership Trends for Ligand Pharmaceuticals Incorporated.

Who sold Ligand Pharmaceuticals Incorporated stock? Who is selling Ligand Pharmaceuticals Incorporated stock?

Ligand Pharmaceuticals Incorporated's stock was sold by a variety of institutional investors in the last quarter, including Oak Ridge Investments LLC, RK Capital Management LLC, Mesirow Financial Investment Management Equity Management, State of New Jersey Common Pension Fund D, Dimensional Fund Advisors LP, Cortina Asset Management LLC, Victory Capital Management Inc. and Kornitzer Capital Management Inc. KS. Company insiders that have sold Ligand Pharmaceuticals Incorporated company stock in the last year include Charles S Berkman, Jason Aryeh, John L Higgins, John W Kozarich, Matthew E Korenberg and Matthew W Foehr. View Insider Buying and Selling for Ligand Pharmaceuticals Incorporated.

Who bought Ligand Pharmaceuticals Incorporated stock? Who is buying Ligand Pharmaceuticals Incorporated stock?

Ligand Pharmaceuticals Incorporated's stock was acquired by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Stifel Financial Corp, Nationwide Fund Advisors, Conestoga Capital Advisors LLC, Ameriprise Financial Inc., Janney Montgomery Scott LLC, Prudential Financial Inc. and Strs Ohio. View Insider Buying and Selling for Ligand Pharmaceuticals Incorporated.

How do I buy Ligand Pharmaceuticals Incorporated stock?

Shares of Ligand Pharmaceuticals Incorporated can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ligand Pharmaceuticals Incorporated's stock price today?

One share of Ligand Pharmaceuticals Incorporated stock can currently be purchased for approximately $140.31.

How big of a company is Ligand Pharmaceuticals Incorporated?

Ligand Pharmaceuticals Incorporated has a market capitalization of $3.06177 billion and generates $108.97 million in revenue each year. The biotechnology company earns ($1,630,000.00) in net income (profit) each year or $0.69 on an earnings per share basis. Ligand Pharmaceuticals Incorporated employs 22 workers across the globe.

How can I contact Ligand Pharmaceuticals Incorporated?

Ligand Pharmaceuticals Incorporated's mailing address is 3911 SORRENTO VALLEY BLVD SUITE 110, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-550-7500 or via email at [email protected]


MarketBeat Community Rating for Ligand Pharmaceuticals Incorporated (NASDAQ LGND)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  295 (Vote Outperform)
Underperform Votes:  164 (Vote Underperform)
Total Votes:  459
MarketBeat's community ratings are surveys of what our community members think about Ligand Pharmaceuticals Incorporated and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 1 Hold Rating, 4 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $145.60 (3.77% upside)

Consensus Price Target History for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

Price Target History for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

Analysts' Ratings History for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/15/2017Craig HallumReiterated RatingBuy$160.00 -> $170.00N/AView Rating Details
11/15/2017HC WainwrightSet Price TargetBuy$159.00N/AView Rating Details
11/13/2017Roth CapitalSet Price TargetBuy$158.00N/AView Rating Details
8/9/2017StephensReiterated RatingOverweight$125.00 -> $137.00LowView Rating Details
8/8/2017Deutsche Bank AGBoost Price TargetHold$103.00 -> $104.00HighView Rating Details
9/28/2016CJS SecuritiesLower Price TargetOutperform$130.00 -> $125.00N/AView Rating Details
3/11/2016SidotiInitiated CoverageBuy$140.00N/AView Rating Details
(Data available from 11/17/2015 forward)

Earnings

Earnings History and Estimates Chart for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

Earnings by Quarter for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

Earnings History by Quarter for Ligand Pharmaceuticals Incorporated (NASDAQ LGND)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/22/2018        
11/9/2017Q3 2017$0.37$0.69$31.04 million$33.38 millionViewN/AView Earnings Details
8/7/2017Q2 2017$0.25$0.67$24.40 million$28.00 millionViewListenView Earnings Details
5/9/2017Q1 2017$0.55$0.39$30.25 million$29.27 millionViewListenView Earnings Details
2/23/2017Q416$1.19($0.15)$40.34 million$38.20 millionViewN/AView Earnings Details
11/3/2016Q316$0.59$0.62$23.64 million$21.62 millionViewN/AView Earnings Details
8/4/2016Q216$0.40$0.50$18.12 million$19.50 millionViewN/AView Earnings Details
5/4/2016Q116$0.67$0.97$26.45 million$29.60 millionViewN/AView Earnings Details
2/10/2016Q415$0.51$0.66$24.71 million$21.20 millionViewListenView Earnings Details
11/9/2015Q315$0.42$0.56$17.80 million$17.70 millionViewN/AView Earnings Details
8/4/2015Q215$0.40$1.63$17.00 million$18.42 millionViewN/AView Earnings Details
5/11/2015Q115$0.12$0.33$13.50 million$14.60 millionViewListenView Earnings Details
2/9/2015Q414$0.48$0.48$23.88 million$23.00 millionViewN/AView Earnings Details
10/27/2014Q314$0.21$0.19$14.60 million$15.00 millionViewListenView Earnings Details
8/4/2014Q214$0.14$0.24$9.73 million$10.60 millionViewN/AView Earnings Details
5/7/2014Q114$0.25$0.35$13.63 million$16.00 millionViewN/AView Earnings Details
2/11/2014Q413$0.19$0.35$13.72 million$14.70 millionViewN/AView Earnings Details
10/30/2013Q213$0.07$0.12$10.81 million$13.00 millionViewN/AView Earnings Details
8/1/2013Q2 2013$0.06$0.07$9.48 million$9.58 millionViewN/AView Earnings Details
5/8/2013Q1 2013$0.09$0.16$10.00 million$11.70 millionViewN/AView Earnings Details
2/13/2013Q4 2012$0.19$12.90 million$13.60 millionViewN/AView Earnings Details
11/5/2012Q312$0.04($0.01)$8.40 million$6.40 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
2017 EPS Consensus Estimate: $2.60
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171$0.43$0.43$0.43
Q2 20171$0.60$0.60$0.60
Q3 20171$0.75$0.75$0.75
Q4 20171$0.82$0.82$0.82
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Ligand Pharmaceuticals Incorporated (NASDAQ LGND)

Insider Ownership Percentage: 14.70%
Insider Trades by Quarter for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
Institutional Ownership by Quarter for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

Insider Trades by Quarter for Ligand Pharmaceuticals Incorporated (NASDAQ LGND)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/17/2017Matthew E KorenbergVPSell6,559$142.63$935,510.17View SEC Filing  
11/16/2017John L HigginsCEOSell5,269$142.53$750,990.57View SEC Filing  
11/16/2017John W KozarichDirectorSell5,000$141.71$708,550.00View SEC Filing  
9/5/2017John L HigginsCEOSell5,000$130.00$650,000.00View SEC Filing  
8/23/2017Jason AryehDirectorSell2,000$127.99$255,980.00View SEC Filing  
8/9/2017Charles S BerkmanVPSell18,625$126.96$2,364,630.00View SEC Filing  
8/9/2017Matthew W FoehrInsiderSell6,100$127.51$777,811.00View SEC Filing  
8/8/2017John L HigginsCEOSell5,483$125.00$685,375.00View SEC Filing  
6/21/2017John L HigginsCEOSell4,666$120.00$559,920.00View SEC Filing  
6/9/2017John L HigginsCEOSell12,000$114.87$1,378,440.00View SEC Filing  
5/12/2017Jason AryehDirectorSell37,247$110.76$4,125,477.72View SEC Filing  
5/12/2017Matthew W FoehrInsiderSell5,621$112.20$630,676.20View SEC Filing  
3/20/2017John L HigginsCEOSell4,000$109.10$436,400.00View SEC Filing  
3/2/2017Matthew W FoehrInsiderSell6,879$103.39$711,219.81View SEC Filing  
2/28/2017Jason AryehDirectorSell32,000$106.35$3,403,200.00View SEC Filing  
11/25/2016Jason AryehDirectorSell18,479$107.31$1,982,981.49View SEC Filing  
11/18/2016Jason AryehDirectorSell6,330$105.28$666,422.40View SEC Filing  
9/22/2016John L HigginsCEOSell3,000$117.34$352,020.00View SEC Filing  
9/7/2016John W KozarichDirectorSell1,000$115.00$115,000.00View SEC Filing  
9/1/2016John W KozarichDirectorSell1,666$105.40$175,596.40View SEC Filing  
8/1/2016John W KozarichDirectorSell1,000$137.57$137,570.00View SEC Filing  
7/1/2016John W KozarichDirectorSell1,000$121.40$121,400.00View SEC Filing  
6/1/2016John W KozarichDirectorSell1,000$117.42$117,420.00View SEC Filing  
5/18/2016Melanie J HermanDirectorSell334$120.50$40,247.00View SEC Filing  
5/6/2016Jason AryehDirectorSell25,000$119.20$2,980,000.00View SEC Filing  
5/2/2016John W KozarichDirectorSell1,000$121.57$121,570.00View SEC Filing  
4/6/2016John W KozarichDirectorSell5,000$115.00$575,000.00View SEC Filing  
3/17/2016Matthew W FoehrCOOSell6,400$96.70$618,880.00View SEC Filing  
3/8/2016Jason AryehDirectorSell6,129$101.18$620,132.22View SEC Filing  
3/7/2016John L HigginsCEOSell10,833$102.47$1,110,057.51View SEC Filing  
1/20/2016John W. KozarichDirectorSell1,666$94.94$158,170.04View SEC Filing  
11/11/2015Melanie J. HermanDirectorSell7,719$101.00$779,619.00View SEC Filing  
8/17/2015David M KnottDirectorSell4,000$95.98$383,920.00View SEC Filing  
8/13/2015David M KnottDirectorSell49,800$96.26$4,793,748.00View SEC Filing  
7/10/2015Charles S BerkmanVPSell14,067$99.14$1,394,602.38View SEC Filing  
6/26/2015Matthew W FoehrCOOSell12,500$100.97$1,262,125.00View SEC Filing  
6/22/2015Matthew W FoehrCOOSell23,046$96.45$2,222,786.70View SEC Filing  
6/10/2015Melanie J HermanCFOSell4,125$93.50$385,687.50View SEC Filing  
6/9/2015John L HigginsCEOSell10,000$92.88$928,800.00View SEC Filing  
6/4/2015Jason AryehDirectorSell1,640$92.68$151,995.20View SEC Filing  
5/20/2015Jason AryehDirectorSell9,240$87.34$807,021.60View SEC Filing  
5/14/2015Nishan M DesilvaCFOSell68,363$83.91$5,736,339.33View SEC Filing  
3/19/2015Sunil PatelDirectorSell4,591$74.42$341,662.22View SEC Filing  
2/10/2015Nishan M DesilvaVPSell2,300$56.34$129,582.00View SEC Filing  
10/15/2014John W KozarichDirectorBuy2,000$45.68$91,360.00View SEC Filing  
10/9/2014Jason AryehDirectorBuy11,000$42.99$472,890.00View SEC Filing  
8/15/2014John L HigginsCEOBuy1,000$54.97$54,970.00View SEC Filing  
6/9/2014Melanie J HermanDirectorSell1,100$69.68$76,648.00View SEC Filing  
5/27/2014Charles S BerkmanVPSell7,166$66.90$479,405.40View SEC Filing  
3/25/2014Bvf Partners P/IlInsiderSell78,226$70.09$5,482,860.34View SEC Filing  
3/19/2014Todd DavisDirectorSell7,500$79.57$596,775.00View SEC Filing  
3/18/2014John LamattinaDirectorSell5,000$78.83$394,150.00View SEC Filing  
2/20/2014Bvf Partners P/Ilmajor shareholderSell422,900$73.81$31,214,249.00View SEC Filing  
2/18/2014David KnottDirectorSell41,900$75.71$3,172,249.00View SEC Filing  
2/14/2014Jason AryehDirectorSell40,320$76.44$3,082,060.80View SEC Filing  
2/14/2014Matthew FoehrCOOSell22,500$79.54$1,789,650.00View SEC Filing  
12/12/2013Matthew FoehrCOOSell6,000$53.40$320,400.00View SEC Filing  
12/6/2013John SharpCFOSell6,000$56.08$336,480.00View SEC Filing  
10/18/2013John L HigginsCEOSell10,000$55.00$550,000.00View SEC Filing  
9/23/2013Bvf Partners P/Ilmajor shareholderSell359,023$44.50$15,976,523.50View SEC Filing  
9/12/2013David KnottDirectorSell160,000$46.78$7,484,800.00View SEC Filing  
8/30/2013Charles BerkmanVPSell28,323$47.54$1,346,475.42View SEC Filing  
8/16/2013Charles BerkmanVPSell14,583$42.63$621,673.29View SEC Filing  
8/16/2013John HigginsCEOSell10,000$42.85$428,500.00View SEC Filing  
8/16/2013John SharpCFOSell7,500$42.75$320,625.00View SEC Filing  
6/28/2013Matthew W FoehrCOOBuy1,059$17.36$18,384.24View SEC Filing  
5/10/2013Charles S BerkmanVPSell4,000$26.66$106,640.00View SEC Filing  
1/23/2013Bvf Partners L P/IlMajor ShareholderBuy39,600$19.78$783,288.00View SEC Filing  
12/14/2012Bvf Partners L P/IlMajor ShareholderBuy5,386$18.63$100,341.18View SEC Filing  
12/6/2012Bvf Partners L P/IlMajor ShareholderBuy50,100$17.94$898,794.00View SEC Filing  
12/5/2012John L HigginsCEOBuy2,000$18.03$36,060.00View SEC Filing  
10/31/2012Bvf Partners L P/IlMajor ShareholderBuy16,591$15.19$252,017.29View SEC Filing  
8/29/2012David M KnottDirectorBuy2,743$16.36$44,875.48View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

Latest Headlines for Ligand Pharmaceuticals Incorporated (NASDAQ LGND)

Source:
DateHeadline
Ligand Pharmaceuticals Incorporated (LGND) Director John W. Kozarich Sells 5,000 SharesLigand Pharmaceuticals Incorporated (LGND) Director John W. Kozarich Sells 5,000 Shares
www.americanbankingnews.com - November 17 at 8:12 PM
Ligand Pharmaceuticals Incorporated (LGND) VP Matthew E. Korenberg Sells 6,559 SharesLigand Pharmaceuticals Incorporated (LGND) VP Matthew E. Korenberg Sells 6,559 Shares
www.americanbankingnews.com - November 17 at 8:12 PM
Ligand Pharmaceuticals Incorporated (LGND) CEO John L. Higgins Sells 5,269 SharesLigand Pharmaceuticals Incorporated (LGND) CEO John L. Higgins Sells 5,269 Shares
www.americanbankingnews.com - November 17 at 8:11 PM
Ultragenyx's rhGUS Gets FDA Nod for Rare Genetic DiseaseUltragenyx's rhGUS Gets FDA Nod for Rare Genetic Disease
finance.yahoo.com - November 17 at 6:31 PM
Ligand Pharmaceuticals, Inc. – Value Analysis (NASDAQ:LGND) : November 15, 2017Ligand Pharmaceuticals, Inc. – Value Analysis (NASDAQ:LGND) : November 15, 2017
finance.yahoo.com - November 17 at 1:16 PM
Ligand Pharma (LGND) Offers Highlights from Todays Analyst Day Event - StreetInsider.comLigand Pharma (LGND) Offers Highlights from Today's Analyst Day Event - StreetInsider.com
www.streetinsider.com - November 15 at 4:07 AM
Ligand Provides Highlights from Today’s Analyst Day EventLigand Provides Highlights from Today’s Analyst Day Event
finance.yahoo.com - November 15 at 4:07 AM
Ligand Pharmaceuticals Incorporated (LGND) Issues FY17 Earnings GuidanceLigand Pharmaceuticals Incorporated (LGND) Issues FY17 Earnings Guidance
www.americanbankingnews.com - November 14 at 9:18 PM
AstraZeneca Gets Positive CHMP Opinion for Asthma CandidateAstraZeneca Gets Positive CHMP Opinion for Asthma Candidate
finance.yahoo.com - November 13 at 1:13 PM
Arena (ARNA) Completes Enrolment in Etrasimod Phase II StudyArena (ARNA) Completes Enrolment in Etrasimod Phase II Study
finance.yahoo.com - November 13 at 1:13 PM
Ligand Reports Third Quarter 2017 Financial ResultsLigand Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 11 at 4:35 PM
Ligand tops 3Q revenue forecastsLigand tops 3Q revenue forecasts
finance.yahoo.com - November 11 at 4:35 PM
Puma (PBYI) Falls Despite Narrower-Than-Expected Q3 LossPuma (PBYI) Falls Despite Narrower-Than-Expected Q3 Loss
finance.yahoo.com - November 11 at 4:35 PM
Xoma: A Lower Risk Way Of Investing In BiotechXoma: A Lower Risk Way Of Investing In Biotech
finance.yahoo.com - November 11 at 4:35 PM
Ligand Pharmaceuticals Incorporated (LGND) Issues Quarterly  Earnings ResultsLigand Pharmaceuticals Incorporated (LGND) Issues Quarterly Earnings Results
www.americanbankingnews.com - November 10 at 12:32 AM
Key Predictions for Q3 Earnings Reports of PBYI, XON, LGNDKey Predictions for Q3 Earnings Reports of PBYI, XON, LGND
finance.yahoo.com - November 8 at 1:48 PM
Prothena (PRTA) Earnings Beat in Q3, Pipeline in FocusProthena (PRTA) Earnings Beat in Q3, Pipeline in Focus
finance.yahoo.com - November 8 at 1:48 PM
Arena Pharmaceuticals (ARNA) Q3 Loss Widens Y/Y, Sales BeatArena Pharmaceuticals (ARNA) Q3 Loss Widens Y/Y, Sales Beat
finance.yahoo.com - November 8 at 1:48 PM
Alnylam's (ALNY) Q3 Earnings, Revenues Miss EstimatesAlnylam's (ALNY) Q3 Earnings, Revenues Miss Estimates
finance.yahoo.com - November 8 at 1:48 PM
Keryx (KERX) Q3 Loss Wider Than Expected, Stock DeclinesKeryx (KERX) Q3 Loss Wider Than Expected, Stock Declines
finance.yahoo.com - November 8 at 1:48 PM
Agenus (AGEN) Reports In Line Loss in Q3, Revenues LagAgenus (AGEN) Reports In Line Loss in Q3, Revenues Lag
finance.yahoo.com - November 8 at 1:48 PM
What's in Store for Ligand (LGND) This Earnings Season?What's in Store for Ligand (LGND) This Earnings Season?
finance.yahoo.com - November 6 at 8:46 PM
Reminder: Ligand to Host Analyst Day on November 14th in New York CityReminder: Ligand to Host Analyst Day on November 14th in New York City
finance.yahoo.com - November 6 at 3:41 PM
Ligand Pharmaceuticals (LGND) versus Asterias Biotherapeutics (AST) Head to Head ComparisonLigand Pharmaceuticals (LGND) versus Asterias Biotherapeutics (AST) Head to Head Comparison
www.americanbankingnews.com - November 5 at 3:40 PM
Is It Time To Buy Ligand Pharmaceuticals Incorporated (LGND)?Is It Time To Buy Ligand Pharmaceuticals Incorporated (LGND)?
finance.yahoo.com - November 5 at 5:07 AM
Strange: Bullish LGND Analysts Actually See -1.3% DownsideStrange: Bullish LGND Analysts Actually See -1.3% Downside
www.nasdaq.com - November 4 at 5:47 AM
Ligand to Participate in the Stephens Fall Investment ConferenceLigand to Participate in the Stephens Fall Investment Conference
finance.yahoo.com - November 4 at 5:47 AM
AMAG Pharma's (AMAG) Q3 Earnings Beat, Lowers '17 OutlookAMAG Pharma's (AMAG) Q3 Earnings Beat, Lowers '17 Outlook
finance.yahoo.com - November 3 at 2:40 PM
PDL BioPharma (PDLI) Q3 Earnings Beat, Revenues Rise Y/YPDL BioPharma (PDLI) Q3 Earnings Beat, Revenues Rise Y/Y
finance.yahoo.com - November 3 at 2:40 PM
Ligand Pharmaceuticals Incorporated (LGND) to Release Quarterly Earnings on ThursdayLigand Pharmaceuticals Incorporated (LGND) to Release Quarterly Earnings on Thursday
www.americanbankingnews.com - November 2 at 3:32 AM
Ligand Pharmaceuticals Incorporated (LGND) Receives Average Recommendation of "Buy" from BrokeragesLigand Pharmaceuticals Incorporated (LGND) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - November 1 at 10:24 AM
Ligand to Report Third Quarter 2017 Results on November 9thLigand to Report Third Quarter 2017 Results on November 9th
finance.yahoo.com - October 25 at 6:41 AM
3 Small, Profitable Biotechs With Fantastic Growth3 Small, Profitable Biotechs With Fantastic Growth
www.fool.com - October 24 at 7:57 AM
Zacks: Brokerages Anticipate Ligand Pharmaceuticals Incorporated (LGND) Will Post Quarterly Sales of $31.22 MillionZacks: Brokerages Anticipate Ligand Pharmaceuticals Incorporated (LGND) Will Post Quarterly Sales of $31.22 Million
www.americanbankingnews.com - October 21 at 10:52 AM
Ligand Pharmaceuticals Incorporated (LGND) Given a $157.00 Price Target by HC Wainwright AnalystsLigand Pharmaceuticals Incorporated (LGND) Given a $157.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - October 18 at 8:58 PM
Zacks Industry Outlook Highlights: Novo, Vertex Pharmaceuticals, Celgene and Ligand PharmaceuticalsZacks Industry Outlook Highlights: Novo, Vertex Pharmaceuticals, Celgene and Ligand Pharmaceuticals
finance.yahoo.com - October 18 at 4:04 PM
Impax Laboratories and Amneal Pharmaceuticals Agree to MergeImpax Laboratories and Amneal Pharmaceuticals Agree to Merge
finance.yahoo.com - October 18 at 4:04 PM
Ligand Pharmaceuticals Incorporated (LGND) Raised to Strong-Buy at Zacks Investment ResearchLigand Pharmaceuticals Incorporated (LGND) Raised to Strong-Buy at Zacks Investment Research
www.americanbankingnews.com - October 14 at 5:52 PM
Ligand Pharmaceuticals Incorporated (LGND) Receives "Buy" Rating from Roth CapitalLigand Pharmaceuticals Incorporated (LGND) Receives "Buy" Rating from Roth Capital
www.americanbankingnews.com - October 11 at 5:20 PM
Forget Teva (TEVA), Buy These 5 Drug Stocks InsteadForget Teva (TEVA), Buy These 5 Drug Stocks Instead
finance.yahoo.com - October 9 at 4:27 PM
CTI BioPharma Corp. (CTIC) vs. Ligand Pharmaceuticals (LGND) Head-To-Head ReviewCTI BioPharma Corp. (CTIC) vs. Ligand Pharmaceuticals (LGND) Head-To-Head Review
www.americanbankingnews.com - October 8 at 8:34 AM
Ligand Pharmaceuticals Incorporated (LGND) Receives Consensus Rating of "Hold" from AnalystsLigand Pharmaceuticals Incorporated (LGND) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - October 7 at 8:50 AM
LGND Crosses Above Average Analyst TargetLGND Crosses Above Average Analyst Target
www.nasdaq.com - October 6 at 3:32 AM
Ligand Pharma (LGND) to Acquire Crystal Bioscience for $25 Million Plus MilestonesLigand Pharma (LGND) to Acquire Crystal Bioscience for $25 Million Plus Milestones
www.streetinsider.com - October 6 at 3:32 AM
HC Wainwright Reaffirms "Buy" Rating for Ligand Pharmaceuticals Incorporated (LGND)HC Wainwright Reaffirms "Buy" Rating for Ligand Pharmaceuticals Incorporated (LGND)
www.americanbankingnews.com - October 5 at 10:08 AM
Ligand Pharma (LGND) to Acquire Crystal Bioscience for $25 Million Plus Milestones - StreetInsider.comLigand Pharma (LGND) to Acquire Crystal Bioscience for $25 Million Plus Milestones - StreetInsider.com
www.streetinsider.com - October 5 at 8:17 AM
Ligand to Acquire Crystal Bioscience, the Leader in Chicken-derived Fully-human Antibody Generation, for $25 Million in Cash plus Additional Potential PaymentsLigand to Acquire Crystal Bioscience, the Leader in Chicken-derived Fully-human Antibody Generation, for $25 Million in Cash plus Additional Potential Payments
finance.yahoo.com - October 5 at 8:17 AM
Ligand Pharmaceuticals Incorporated (LGND) Releases FY17 Earnings GuidanceLigand Pharmaceuticals Incorporated (LGND) Releases FY17 Earnings Guidance
www.americanbankingnews.com - October 4 at 5:24 PM
Head to Head Survey: Ligand Pharmaceuticals (LGND) vs. The CompetitionHead to Head Survey: Ligand Pharmaceuticals (LGND) vs. The Competition
www.americanbankingnews.com - October 4 at 2:10 AM
Ligand Pharmaceuticals, Inc. :LGND-US: Earnings Analysis: Q2, 2017 By the Numbers : September 29, 2017Ligand Pharmaceuticals, Inc. :LGND-US: Earnings Analysis: Q2, 2017 By the Numbers : September 29, 2017
finance.yahoo.com - October 2 at 12:23 PM

Social Media

Financials

Chart

Ligand Pharmaceuticals Incorporated (NASDAQ LGND) Chart for Friday, November, 17, 2017
Loading chart…

This page was last updated on 11/17/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.